Multiple complex coronary atherosclerosis in diabetic patients with acute myocardial infarction: a three-vessel optical coherence tomography study

Masashi Fukunaga¹, MD; Kenichi Fujii^{1*}, MD; Tsuyoshi Nakata¹, MD; Masahiko Shibuya¹, MD; Kojiro Miki¹, MD; Daizo Kawasaki¹, MD; Motomaru Masutani², MD; Masaaki Kawabata-Lee¹, MD; Mitsumasa Ohyanagi², MD; Tohru Masuyama¹, MD

1. Cardiovascular Division, Hyogo College of Medicine, Nishinomiya, Japan; 2. Division of Coronary Heart Disease, Hyogo College of Medicine, Nishinomiya, Japan

KEYWORDS

• acute myocardial infarction

• diabetes mellitus

• optical coherence tomography

Abstract

Aims: The main cause of acute myocardial infarction (AMI) is the disruption of a thin-cap fibroatheroma (TCFA) and subsequent thrombosis. Mortality increases in diabetic patients due to cardiovascular events; there may be differences in the vulnerable plaques between diabetic and non-diabetic patients. We used optical coherence tomography (OCT) to assess the incidence of vulnerable plaques in diabetic patients with AMI.

Methods and results: OCT was performed in all three major coronary arteries of 70 AMI patients: 48 nondiabetic and 22 diabetic patients. The OCT criterion for TCFA was the presence of both a lipid-rich plaque composition and a fibrotic cap thickness of $\leq 65 \mu m$. A ruptured plaque contains a cavity in contact with a lumen and a residual fibrous cap. OCT identified 68 plaque ruptures (1.0 per patient; range, 0-3) and 162 TCFAs (2.3 per patient; range, 0-5). The incidences of plaque rupture and TCFA at culprit lesions were similar. However, non-culprit-lesion TCFAs were observed more frequently in diabetic patients than in non-diabetic patients.

Conclusions: Although the prevalence of vulnerable plaque in culprit lesions was similar between diabetic and non-diabetic patients, vulnerable plaques were observed in non-culprit lesions more in diabetic patients than in non-diabetic patients.

**Corresponding author: Hyogo College of Medicine, Cardiovascular Division, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan. E-mail: kfujii@hyo-med.ac.jp*

Introduction

Atherosclerotic cardiovascular disease, in particular coronary heart disease, is a major cause of morbidity and mortality in patients with diabetes mellitus $(DM)^1$. DM is generally considered to be a potent risk factor for the development and progression of coronary atherosclerosis. Furthermore, late mortality rate is higher in diabetic patients than in non-diabetic patients among those who have survived acute myocardial infarction (AMI)^{2,3}. Immediately following an AMI, the prognosis that they will suffer in-hospital mortality due to congestive heart failure is nearly twice as high for diabetic patients^{4,5}. The high late mortality rate seen in diabetic patients following an AMI is primarily related to recurrent myocardial infarction^{6,7}. Recently, it has been shown that there are multiple vulnerable plaques besides the "culprit" stenosis in individual patients with AMI^{8,9}, and that the presence of multiple vulnerable plaques is associated with an increased recurrence of acute coronary events leading to AMI8 . Other groups showed that plaque morphology is closely related to the plaque disruption and thrombosis, leading to AMI^{10,11}. Specifically, the precursor for later ruptures is likely to be characterised by a large lipid core with an overlying thin fibrous cap measuring $\leq 65 \mu m$ in thickness, i.e., thin-cap fibroatheromas $(TCFAs)¹²$.

Unfortunately, TCFAs are not accurately assessable with current imaging modalities such as angiography, intravascular ultrasound and angioscopy, due to their insufficient resolution or lack of penetration into the plaque. Optical coherence tomography (OCT) is an optical analogue of intravascular ultrasound that allows high resolution (approximately 10 µm) tomographic imaging, and is used to assess TCFAs reliably and reproducibly^{13,14}. The current study employed OCT to assess whether there is a difference in the incidence of complex plaque morphology, including TCFA, between diabetic and non-diabetic AMI patients.

Methods

STUDY POPULATION

A prospective but non-consecutive series of 92 patients with suitable vascular anatomy, who were scheduled for primary percutaneous coronary intervention (PCI) to treat AMI, underwent OCT examination of all three major epicardial coronary arteries. In this OCT study, ST-segment elevation AMI patients (ST-segment elevation of at least 0.1 mV in two or more continuous electrocardiographic leads) and non-ST-segment elevation AMI patients were included. AMI was defined as continuous chest pain at rest with abnormal levels of creatine kinase-MB. Patients with a history of myocardial infarction, a history of coronary artery bypass grafts (CABG), and severe left ventricular dysfunction were not enrolled because of the potential difficulty in acquiring and interpreting OCT images with such conditions. Identification of culprit lesions involved the combination of left ventricular wall motion abnormalities, ECG findings, and angiographic lesion morphology^{13,15}. Patients were considered as having DM if they were on medical treatment for DM or fasting blood sugar level \geq 126 mg/dl. The population was divided into two groups according to the presence

or absence of DM. The institutional review board approved the study, and all patients provided written informed consent before participation.

OCT IMAGING PROTOCOL

All OCT examinations were performed after intracoronary administration of 3-5 mg isosorbide dinitrate. An over-the-wire occlusion balloon catheter (OBC) (Helios; LightLab Imaging Inc., Westford, MA, USA) was advanced over a 0.014-inch angioplasty guidewire to the culprit lesion and the lesion was crossed with the catheter. The guidewire was then removed from the OBC inner lumen and a 0.016-inch imaging wire (ImagingWire; LightLab Imaging Inc., Westford, MA, USA) was inserted through the OBC. With the ImagingWire held in place across the culprit lesion, the OBC was withdrawn until the balloon was positioned proximal to the culprit lesion. Then, the occlusion balloon was inflated to between 0.4 and 0.6 atm while lactated Ringer's solution was infused from the distal tip of the OBC at 0.5 ml/sec to flush blood from the imaging field. An imaging run was performed from the distal segment through the lesion to the proximal segment of the culprit lesion using automated transducer pullback at 1.0 mm/sec. After the evaluation of the OCT image of the lesion, PCI with stenting was performed in the usual manner such that TIMI grade 3 flow was achieved.

Following PCI treatment of the culprit lesion, OCT examinations of all three major coronary arteries were performed. The arteries were imaged continuously over a 20 to 50 mm length from the distal segment to the ostium. Normally three to five OCT pullbacks were repeated step by step to image one coronary artery. Only the most proximal 3 mm segments of the arteries were not imaged by OCT as that segment was obscured by the occlusion balloon. During this procedure, ST-segment elevation, patient symptoms, and haemodynamics were observed carefully.

OCT ANALYSIS

OCT images were analysed using proprietary software from Light-Lab Imaging, Inc. (Westford, MA, USA) by two independent observers who were blinded to the clinical presentations using validated criteria for plaque characterisation^{13,16}. Qualitative OCT plaque composition assessment was performed for each plaque. Distinction of two separate plaques in the same artery (i.e., culprit versus non-culprit lesion) required a ≥5 mm non-atherosclerotic reference segment dividing them; otherwise, it was considered to be one long lesion¹⁷.

The size of an OCT-identified lipid lesion was quantified as the number of quadrants displaying the lipid pool on the cross-sectional OCT image. When lipid was present in ≥ 1 quadrant in any of the images within a plaque, it was considered a lipid-rich plaque. For each plaque categorised to be lipid-rich, the cross-sectional still frame image displaying the most quadrants subtended by the lipid pool was selected for analysis. For all plaques containing a lipid pool, the covering fibrous cap was measured at its thinnest part five times, the minimum and maximum values neglected, and the average of the three remaining values computed to represent the fibrous

n

n

cap thickness. For OCT image analysis, we defined a TCFA as a lipid-rich plaque with a fibrous cap ≤ 65 µm at its thinnest point¹³ **(Figure 1A)**. A plaque rupture was defined as a plaque containing a cavity which was in contact with the lumen which had any overlying residual fibrous cap fragment **(Figure 1B)**.

ANGIOGRAPHIC ANALYSIS

Quantitative coronary angiography was analysed using a computerassisted, automated edge-detection algorithm (CMS; Medis, Leiden, The Netherlands) using standard measurements by an independent observer who was blinded to clinical and OCT information. An MLD=0.0 was assumed in the presence of a total occlusion.

Statistics

Continuous variables were reported as mean±SD. The unpaired student's t-test was used to test the differences between two sets of data with normal distributions. If normality tests failed, the Mann-Whitney U test was used. Categorical variables were reported as frequencies and compared using chi-square statistics. To evaluate interobserver agreement for TCFA, all OCT images were reviewed and a subset of plaques was classified by a second observer and the κ statistic was calculated. Agreement between observers for characterising TCFA was good (κ =0.88) in this study. A p value of <0.05 was considered statistically significant.

Results

BASELINE PATIENT CHARACTERISTICS

Of the 92 enrolled patients, 15 patients did not undergo three-vessel OCT examinations because of left main or severe three-vessel disease. Four were excluded from analysis because TIMI grade 3 flow was not achieved after PCI treatment of the culprit lesion. Three patients were also excluded from OCT image analysis because one or two coronary arteries were not successfully imaged by OCT due to arterial tortuosity or stenosis. Accordingly, a total of 70 patients with AMI were prospectively included in the study.

The average time from symptom onset to PCI was 5.9±3.8 hours for ST-elevation AMI and 14.8±13.8 hours for non-ST-elevation AMI ($p<0.01$). There were 48 non-diabetic and 22 diabetic patients. Of the 22 diabetic patients, six were on diet therapy, 12 were treated with oral hypoglycaemic drugs, and only four required insulin therapy. Baseline clinical characteristics and angiographic findings are shown in **Table 1**. There was no significant difference between diabetic and non-diabetic patients in baseline clinical characterisation and angiographic findings except for a higher level of serum HDL cholesterol in non-diabetic patients. In addition, there were no significant differences in patient characterisation between insulintreated diabetic patients and non-insulin-treated diabetic patients. However, diabetic patients requiring insulin treatment had significantly higher baseline percent haemoglobin A1C (13.8±3.2 vs. 6.8 ± 1.1 , p<0.001) and tended to have higher baseline plasma fasting glucose level (169±29 vs. 141±9.0 mg/dl) than the diabetic patients treated without insulin.

OCT FINDINGS

The total length of all three coronary arteries imaged by OCT was similar between diabetic and non-diabetic patients: 76±32 vs. 85 ± 29 mm in the LAD, 58 ± 31 vs. 69 ± 28 mm in the LCX, and 96±43 vs. 107±42 mm in the RCA. Sixty-eight plaque ruptures (mean 1.0 per patient; range 0-3) and 162 TCFAs (mean 2.3 per patient; range 0-5) were identified by OCT. The mean value for the TCFA minimum fibrous-cap thickness was 57.9±6.3 µm in diabetic patients and 56.3 ± 5.8 µm in non-diabetic patients (p=0.2). The location of TCFAs was similar between diabetic and non-diabetic patients (proximal: 43% vs. 38%; middle: 33% vs. 45%; and distal:

Figure 1. *Representative optical coherence tomography images of a thin-cap fibroatheroma (TCFA) and a plaque rupture. Lipid-rich (L) plaque covered by a thin fibrous cap (arrowheads) indicates a TCFA (A). Plaque rupture contains a cavity with an overlying residual fibrous cap fragment (arrows) (B).*

n

Table 1. Baseline clinical characteristics and angiographic findings.

24% vs. 17%, respectively). The distribution of plaque ruptures was also similar between diabetic and non-diabetic patients (proximal: 50% vs. 44%; middle: 20% vs. 32%; and distal: 30% vs. 24%, respectively). Although the mean numbers of plaque ruptures per patient were similar between the two patient groups $(1.0\pm1.0$ for diabetic vs. 1.0 ± 0.9 for non-diabetic, $p=0.9$), the total number of TCFAs was significantly larger in diabetic patients than in non-diabetic patients (3.1±1.2 vs. 2.0±1.3, p<0.001) **(Figure 2)**. The incidences of plaque rupture and TCFA within the culprit lesion were similar

Figure 2. *The frequency of plaque rupture and thin-cap fibroatheroma (TCFA) detected in the culprit lesion between diabetic and non-diabetic groups. No significant differences existed between the two groups.*

between the two groups. Among the 70 patients, however, 54 (77%) had at least one TCFA discovered in a non-culprit lesion: 100% (22/22) in diabetic patients and 67% (32/48) in non-diabetic patients (p=0.002). Similarly, 22 (31%) had at least one plaque rupture somewhere other than the culprit lesion: 27% (6/22) in diabetic patients and 33% (16/48) in non-diabetic patients (p=0.6). Percentage distribution of TCFAs and plaque ruptures other than those within the culprit lesion is shown in **Figure 3**. Multiple TCFAs were identified in 20 diabetic patients (91%) and 28 non-diabetic patients (58%) (p=0.006), and multiple plaque ruptures were identified in six diabetic patients (27%) and 14 non-diabetic patients (29%) (p=0.8).

Discussion

Mortality from myocardial infarction is markedly higher in diabetic patients than in non-diabetic patients^{18,19}. Despite an improvement in the management of patients with acute coronary syndromes, the syndrome is still linked to a substantially increased morbidity and mortality among diabetic patients, as demonstrated by the OASIS and GUSTO II trials $20,21$. Since the prevalence of DM in patients with AMI is high, and the prevalence in the general population is expected to increase during the coming decades²², management of diabetic patient cohorts will substantially affect total morbidity and mortality rates in coronary heart disease.

Previous studies have reported that plaque rupture occurs not only within AMI culprit lesions but also in non-culprit lesions in patients with various clinical presentations²³, suggesting that some plaque

Figure 3*. Percentage distribution of coronary thin-cap fibroatheromas (TCFAs) and previous plaque ruptures detected in non-culprit lesions. In 77% of cases, at least one TCFA was found. Similarly, in 31% of patients, at least one plaque rupture was identified.*

ruptures lead to clinical manifestations whereas others remain asymptomatic and heal with subsequent fibrosis. However, DM is characterised by elevated concentrations of procoagulant factors and decreased concentration of antithrombotic factors²⁴. Corti et al²⁵ identified significant reductions in tissue factor activity and blood thrombogenicity in diabetic patients with improved glycaemic control. These observations highlight the concept of high-risk blood in the pathophysiology of diabetic atherosclerosis leading to coronary thrombosis. Therefore, diabetic patients who have coronary atherosclerosis comprising TCFAs, which are known to be precursor lesions vulnerable to plaque rupture, may have a higher risk of coronary thrombosis following plaque rupture compared with non-diabetic patients. Thus, it is clinically important to improve glycaemic control for the reduction of the incidence of adverse cardiovascular events.

It has been reported that insulin resistance is associated with macrophage upregulation of CD36 protein with an increased uptake of oxidised low-density lipoprotein²⁶. Hyperglycaemia increases macrophage matrix metalloproteinase expression 27 , which is known to play a major role in atherosclerosis and plaque instability by remodelling the extracellular matrix²⁸. In addition, matrix metalloproteinase 2 is a marker for microangiopathy in children with type 1 diabetes²⁹, suggesting a pivotal role for macrophages in the pathogenesis of diabetic atherosclerosis. These findings may affect the plaque instability not only at the culprit lesion but also throughout the entire coronary tree and therefore also non-culprit lesions.

In the present three-vessel OCT study, the overall frequency of TCFA was 2.3 per patients with AMI. In accordance with the current study, Hong et al³⁰ reported that there was an average of 2.5 virtualhistology-derived TCFAs per patient with acute coronary syndrome in a three-vessel virtual histology intravascular ultrasound study. In a pathologic study by Kolodgie et a^{31} there was an average of three TCFAs in male patients dying with acute myocardial infarction and/ or acute plaque rupture. The different frequency of TCFA in the pathologic and OCT studies may be because of different diagnostic methods, clinical presentations or demographics of the study population, number of study patients, and definitions of a TCFA. Furthermore, recently Feng et al³² reported that there was no difference found in the frequencies of vulnerable plaque, including TCFA,

plaque rupture, and plaque erosion, between diabetic and non-diabetic patients with unstable angina pectoris. This discrepancy between the previous OCT study and the current study can be explained by differences in methods. In the current study, OCT examinations were performed in all three major coronary arteries even if an angiogram did not show stenosis in the non-infarct-related artery. On the other hand, only one artery was imaged by OCT in most cases in the previous OCT study. Another explanation for the discrepancy may be differences in population sample and selection.

Limitations

This study was a single-centre study with a relatively small study population. Further multicentre studies are required to confirm the results in a larger population of patients. Although the study was performed prospectively, the use of pre-intervention OCT and the decision to perform three-vessel OCT imaging were at the discretion of the operator. Some ruptured plaques with small cavities may have evaded detection by OCT, especially when the cavity was filled by thrombus at the culprit site. The proximal 3 mm of the coronary arteries were not imaged by OCT due to the need to occlude via proximal balloon inflation. In the current study, patients with triple vessel disease were excluded because of the potential difficulty in acquiring and interpreting OCT images. Therefore, some selection bias may be inherent. Finally, as mentioned above, we did not attempt three-vessel OCT examinations when patients were on cardiogenic shock, high-grade AV block, and had severe renal failure. Therefore, approximately one third of STEMI patients were not thought to be eligible for enrolment in the study. OCT examinations were attempted only when the patients' haemodynamic parameters were stable, and non-culprit arteries were imaged after the successful treatment of culprit lesions. Furthermore, STsegment elevation, patient symptoms, and haemodynamics were observed carefully during the OCT procedure. It is necessary to establish safety, so they must be performed carefully.

OCT of non-culprit vessels in patients with a recent myocardial infarction may be associated with the potential risk of complications. Therefore, only experienced operators performed these procedures in well-selected patients with a favourable anatomy.

Conclusion

Although the prevalence of vulnerable plaque in the culprit lesion was similar between diabetic and non-diabetic patients, diabetic patients had a larger number of vulnerable plaques which had developed elsewhere compared to non-diabetic patients. This difference suggests an increased vulnerability for plaque rupture leading to coronary thrombosis in patients with diabetes mellitus.

Acknowledgements

The authors thank the staff in the cardiac catheterisation laboratory in Hyogo College of Medicine, Nishinomiya, Japan for their excellent assistance during the study.

Conflict of interest statement

The authors have no conflicts of interest to declare.

References

1. Consensus development conference on the diagnosis of coronary heart disease in people with diabetes: 10–11 February 1998, Miami, Florida: American Diabetes Association. *Diabetes Care*. 1998;21:1551-9.

2. Aronson D, Rayfield EJ, Chesebro JH. Mechanisms determining course and outcome of diabetic patients who have had acute myocardial infarction. *Ann Intern Med*. 1997;126:296-306.

3. Abbott RD, Donahue RP, Kannel WB, Wilson PW. The impact of diabetes on survival following myocardial infarction in men vs women. The Framingham study. *JAMA*. 1988;260:3456-60.

4. Miettinen H, Lehto S, Salomaa V, Mähönen M, Niemelä M, Haffner SM, Pyörälä K, Tuomilehto J. Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group. *Diabetes Care*. 1998;21:69-75.

5. Milo C, Reicher-Reiss H, Goldbourt U, Boyko V, Behar S. Comparison of prognosis of acute myocardial infarction in insulintreated diabetic women versus men. The SPRINT Study Group. *Am J Cardiol*. 1994;74:1275-6.

6. Lee KL, Woodlief LH, Topol EJ, Weaver WD, Betriu A, Col J, Simoons M, Aylward P, Van de Werf F, Califf RM. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators. *Circulation*. 1995;91:1659-68.

7. Zuanetti G, Latini R, Maggioni AP, Santoro L, Franzosi MG. Influence of diabetes on mortality in acute myocardial infarction: data from the GISSI-2 study. *J Am Coll Cardiol*. 1993;22:1788-94.

8. Davies M, Thomas A. Thrombosis and acute coronary artery lesions in sudden cardiac ischemic death. *N Engl J Med*. 1984;310:1137-40.

9. Goldstein JA, Demetriou D, Grines CL, Pica M, Shoukfeh M, O'Neill WW. Multiple complex coronary plaques in patients with acute myocardial infarction. *N Engl J Med*. 2000;343:915-22.

10. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. *N Engl J Med*. 1992;326:242-50.

11. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. *Arterioscler Thromb Vasc Biol*. 2000;20:1262-75.

12. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, Badimon JJ, Stefanadis C, Moreno P, Pasterkamp G, Fayad Z, Stone PH, Waxman S, Raggi P, Madjid M, Zarrabi A, Burke A, Yuan C, Fitzgerald PJ, Siscovick DS, de Korte CL, Aikawa M, Airaksinen KE, Assmann G, Becker CR, Chesebro JH, FarbA, Galis ZS, Jackson C, Jang IK, Koenig W, Lodder RA, March K, Demirovic J, Navab M, Priori SG, Rekhter MD, Bahr R, Grundy SM, Mehran R, Colombo A, Boerwinkle E, Ballantyne C, Insull W Jr, Schwartz RS, Vogel R, Serruys PW, Hansson GK, Faxon DP, Kaul S, Drexler H, Greenland P, Muller JE, Virmani R, Ridker PM, Zipes DP, Shah PK, Willerson JT. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part 1. *Circulation*. 2003;108:1664-72.

13. Jang IK, Tearney GJ, MacNeill B, Takano M, Moselewski F, Iftima N, Shishkov M, Houser S, Aretz HT, Halpern EF, Bouma BE. In vivo characterization of coronary atherosclerotic plaque by use of optical coherence tomography. *Circulation*. 2005;111:1551-5.

14. Kume T, Akasaka T, Kawamoto T, Okura H, Watanabe N, Toyota E, Neishi Y, Sukmawan R, Sadahira Y, Yoshida K. Measurement of the thickness of the fibrous cap by optical coherence tomography. *Am Heart J*. 2006;152:755.e1-4.

15. Hong MK, Mintz GS, Lee CW, Kim YH, Lee SW, Song JM, Han KH, Kang DH, Song JK, Kim JJ, Park SW, Park SJ. Comparison of coronary plaque rupture between stable angina and acute myocardial infarction: a three-vessel intravascular ultrasound study in 235 patients. *Circulation*. 2004;110:928-33.

16. Yabushita H, Bouma BE, Houser SL, Aretz HT, Jang IK, Schlendorf KH, Kauffman CR, Shishkov M, Kang DH, Halpern EF, Tearney GJ. Characterization of human atherosclerosis by optical coherence tomography. *Circulation*. 2002;106:1640-5.

17. Maehara A, Mintz GS, Bui AB, Walter OR, Castagna MT, Canos D, Pichard AD, Satler LF, Waksman R, Suddath WO, Laird JR Jr, Kent KM, Weissman NJ. Morphologic and angiographic features of coronary plaque rupture detected by intravascular ultrasound. *J Am Coll Cardiol*. 2002;40:904-10.

18. Otter W, Kleybrink S, Doering W, Standl E, Schnell O. Hospital outcome of acute myocardial infarction in patients with and without diabetes mellitus. *Diabet Med*. 2004;21:183-7.

19. Norhammar A, Malmberg K, Diderholm E, Lagerqvist B, Lindahl B, Rydén L, Wallentin L. Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization. *J Am Coll Cardiol*. 2004;43:585-91.

20. Malmberg K, Yusuf S, Gerstein HC, Brown J, Zhao F, Hunt D, Piegas L, Calvin J, Keltai M, Budaj A. Impact of diabetes on long-term prognosis in patients with unstable angina and non–Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. *Circulation*. 2000;102:1014-9.

21. McGuire DK, Emanuelsson H, Granger CB, Magnus Ohman E, Moliterno DJ, White HD, Ardissino D, Box JW, Califf RM, Topol EJ. Influence of diabetes mellitus on clinical outcomes across the spectrum

n

of acute coronary syndromes. Findings from the GUSTO-IIb study. GUSTO IIb Investigators. *Eur Heart J*. 2000;21:1750-8.

22. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. *Diabetes Care*. 1998;21:1414-31.

23. Fujii K, Kobayashi Y, Mintz GS, Takebayashi H, Dangas G, Moussa I, Mehran R, Lansky AJ, Kreps E, Collins M, Colombo A, Stone GW, Leon MB, Moses JW. Intravascular ultrasound assessment of ulcerated ruptured plaques: a comparison of culprit and nonculprit lesions of patients with acute coronary syndromes and lesions in patients without acute coronary syndromes. *Circulation*. 2003; 108:2473-8.

24. Schneider DJ, Sobel BE. Diabetes and thrombosis. In: Diabetes and Cardiovascular Disease. Johnstone MT, Veves A, Eds. Totowa NJ, Humana Press, 2001.

25. Corti R, Fuster V, Badimon JJ. Pathogenetic concepts of acute coronary syndromes. *J Am Coll Cardiol*. 2003;41:7S-14S.

26. Liang CP, Han S, Okamoto H, Carnemolla R, Tabas I, Accili D, Tall AR. Increased CD36 protein as a response to defective insulin signaling in macrophages. *J Clin Invest*. 2004;113:764-73.

27. Death AK, Fisher EJ, McGrath KC, Yue DK. High glucose alters matrix metalloproteinase expression in two key vascular

cells: potential impact on atherosclerosis in diabetes. *Atherosclerosis*. 2003;168:263-9.

28. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. *Circ Res*. 2002;90:251-62.

29. Derosa G, Avanzini MA, Geroldi D, Fogari R, Lorini R, De Silvestri A, Tinelli C, Rondini G, D'Annunzio G. Matrix metalloproteinase 2 may be a marker of microangiopathy in children and adolescents with type 1 diabetes. *Diabetes Care*. 2004;27:273-4.

30. Hong MK, Mintz GS, Lee CW, Lee JW, Park JH, Park DW, Lee SW, Kim YH, Cheong SS, Kim JJ, Park SW, Park SJ. A threevessel virtual histology intravascular ultrasound analysis of frequency and distribution of thin-cap fibroatheromas in patients with acute coronary syndrome or stable angina pectoris. *Am J Cardiol*. 2008;101:568-72.

31. Kolodgie FD, Virmani R, Burke, AP, Farb, A, Weber DK, Kutys R, Finn AV, Gold HK. Pathologic assessment of the vulnerable human coronary plaque. *Heart*. 2004;90:1385-91.

32. Feng T, Yundai C, Lian C, Zhijun S, Changfu L, Jun G, Hongbin L. Assessment of coronary plaque characteristics by optical coherence tomography in patients with diabetes mellitus complicated with unstable angina pectoris. *Atherosclerosis*. 2010;213:482-5.